ENSC
Ensysce Biosciences, Inc.·Healthcare
0.46
4.029%(−0.02)
Market ClosedLast Updated: — ET
52W L: $0.3152W H: $4.85
ENSC NEWS
accessnewswire.com
4d ago
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a second convertible preferred stock financing of $2 million under prior commitment in November 2025 of up to $20 million funding available over 24 months. The capital will maintain Ensysce's flagship analgesic programs, while supporting general corporate initiatives.
accessnewswire.com
Mar 30
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful progress for Ensysce, marked by significant clinical advancement, productive regulatory engagement, and continued strengthening of our intellectual property portfolio," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences.
defenseworld.net
Mar 26
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Down 59.3% in March
Ensysce Biosciences, Inc. (NASDAQ: ENSC - Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 132,839 shares, a drop of 59.3% from the February 26th total of 326,647 shares. Approximately 3.8% of the shares of the stock are
accessnewswire.com
Mar 4
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the successful initiation of its live "Ask Me Anything" (AMA) series on March 4, 2024.The event reinforced the Company's commitment to transparency, accessibility, and open dialogue with its community. A replay of the AMA series is available on the Company's website here.
accessnewswire.com
Mar 3
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology. The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue.
benzinga.com
Feb 27
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review
Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value.
